ADVFN - Advanced Financial Network.
HOME» NYSE » S » SGP Stock Price » SGP Stock News

Schering Plough Share News

 Schering-plough Corp. Stock Price
SGP Stock Price
 Schering-plough Corp. Stock Chart
SGP Stock Chart
 Schering-plough Corp. Stock News
SGP Stock News
 Schering-plough Corp. Company Information
SGP Company Information
 Schering-plough Corp. Stock Trades
SGP Stock Trades

CORRECT: Schering-Plough 3Q Earnings Down 16% On Charges

("Schering-Plough 3Q Earnings Down 16% On Charges," published at 6:43 a.m. EDT, misstated the company's year-ago profit. A corrected story follows.) DOW JONES NEWSWIRES Schering-Plough Corp.'s (SGP) third-quarter profit fell 16% on increased charges while the company saw a 5% drop in sales of the cholesterol drugs it sells jointly with merger partner Merck & Co. (MRK) The companies' joint venture has been under pressure since an early 2008 study raised questions about the safety and effectiveness of Vytorin and Zetia. Meanwhile, the $49 billion Schering-Merck deal announced in March remains on track to close in the current quarter. Merck is buying Schering to diversify its pipeline, a move sparked by continuing generic competition, pricing pressure and difficulty in bringing new drugs to market. Schering-Plough's earnings dropped to $515 million, or 29 cents a share, from $614 million, or 35 cents a share, a year earlier. Excluding acquisition-related charges and other impacts, earnings rose to 40 cents a share from 39 cents a share. Net sales fell 1.7% to $4.5 billion, reflecting a 6-percentage-point hit from currency changes. Analysts surveyed by Thomson Reuters were expecting earnings, excluding items, of 40 cents a share on revenue of $4.47 billion. Gross margin fell to 61.8% from 62% on the charges, and fell 1 percentage point excluding them on the currency changes. Three-fifths of the cholesterol venture's sales drop was due to the foreign-exchange fluctuations. Sales slid 10% in the U.S. Among Schering-Plough's non-cholesterol treatments, sales of arthritis drug Remicade rose 8%, or 18% excluding currency changes, while allergy treatment Nasonex saw a 3% increase, also held back by foreign exchange rates. Cancer drug Temodar grew 2%. Schering-Plough shares closed Wednesday at $29.01 and didn't trade premarket. The stock is up 70% this year. Merck is expected to report its results later Thursday. -By Mike Barris and Kevin Kingsbury, Dow Jones Newswires; 212-416-2330; [email protected]

Stock News for Schering Plough (SGP)
No Recent News Available

Schering Plough and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations